Greg Zante

CIK: 0001264949

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)17 (60.7%)

Position reduction

Option Exercises (M)4 (14.3%)

Derivative conversions

Awards (A)7 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VKTX

Viking Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (28 total)

VKTX
Viking Therapeutics, Inc.
Jul 29, 2026
Sale(S)
Direct
21.2K shares at avg. $33.47$710K
VKTX
Viking Therapeutics, Inc.
Jul 28, 2026
Award(A)
Direct
31.7K shares-
VKTX
Viking Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
13.9K shares at avg. $33.38$464K
VKTX
Viking Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
10.3K shares at avg. $34.24$353K
VKTX
Viking Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
1.5K shares at avg. $32.09$48K
VKTX
Viking Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
32K shares at avg. $32.30$1.0M
VKTX
Viking Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
41K shares-
VKTX
Viking Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
32K shares-
VKTX
Viking Therapeutics, Inc.
Oct 28, 2025
Sale(S)
Direct
6.2K shares at avg. $35.00$216K
VKTX
Viking Therapeutics, Inc.
Oct 27, 2025
Award(A)
Direct
11.1K shares-
VKTX
Viking Therapeutics, Inc.
Jul 3, 2025
Sale(S)
Direct
4.3K shares at avg. $27.76$118K
VKTX
Viking Therapeutics, Inc.
Jul 2, 2025
Award(A)
Direct
7.7K shares-
VKTX
Viking Therapeutics, Inc.
Jan 6, 2025
Sale(S)
Direct
45.6K shares at avg. $42.69$1.9M
VKTX
Viking Therapeutics, Inc.
Jan 6, 2025
Sale(S)
Direct
4.7K shares at avg. $43.32$204K
VKTX
Viking Therapeutics, Inc.
Jan 3, 2025
Award(A)
Direct
21.7K shares-
VKTX
Viking Therapeutics, Inc.
Jan 3, 2025
Award(A)
Direct
44.5K shares-
VKTX
Viking Therapeutics, Inc.
Oct 28, 2024
Sale(S)
Direct
9.3K shares at avg. $76.94$713K
VKTX
Viking Therapeutics, Inc.
Oct 28, 2024
Sale(S)
Direct
23.1K shares at avg. $77.68$1.8M
VKTX
Viking Therapeutics, Inc.
Oct 28, 2024
Sale(S)
Direct
15.8K shares at avg. $78.69$1.2M
VKTX
Viking Therapeutics, Inc.
Oct 28, 2024
Sale(S)
Direct
6.1K shares at avg. $79.78$483K
VKTX
Viking Therapeutics, Inc.
Oct 28, 2024
Sale(S)
Direct
8K shares at avg. $80.65$643K
VKTX
Viking Therapeutics, Inc.
Oct 28, 2024
Sale(S)
Direct
1.2K shares at avg. $81.44$98K
VKTX
Viking Therapeutics, Inc.
Oct 28, 2024
Exercise(M)
Direct
4.3K shares at avg. $4.68$20K
VKTX
Viking Therapeutics, Inc.
Oct 28, 2024
Exercise(M)
Direct
12.8K shares at avg. $7.77$99K
VKTX
Viking Therapeutics, Inc.
Oct 28, 2024
Exercise(M)
Direct
26K shares at avg. $5.80$151K

		Type	Shares	Price		Ownership
Jul 29, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	21,217	$33.47	$710,141	Direct
Jul 28, 2026	VKTX Viking Therapeutics, Inc.	Award(A)	31,667	-	$0	Direct
Jan 5, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	13,900	$33.38	$464,021	Direct
Jan 5, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	10,300	$34.24	$352,635	Direct
Jan 5, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	1,500	$32.09	$48,133	Direct
Jan 5, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	31,961	$32.30	$1,032,180	Direct
Jan 2, 2026	VKTX Viking Therapeutics, Inc.	Award(A)	41,000	-	$0	Direct
Jan 2, 2026	VKTX Viking Therapeutics, Inc.	Award(A)	32,049	-	$0	Direct
Oct 28, 2025	VKTX Viking Therapeutics, Inc.	Sale(S)	6,185	$35.00	$216,481	Direct
Oct 27, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	11,117	-	-	Direct
Jul 3, 2025	VKTX Viking Therapeutics, Inc.	Sale(S)	4,266	$27.76	$118,428	Direct
Jul 2, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	7,667	-	-	Direct
Jan 6, 2025	VKTX Viking Therapeutics, Inc.	Sale(S)	45,609	$42.69	$1,946,993	Direct
Jan 6, 2025	VKTX Viking Therapeutics, Inc.	Sale(S)	4,700	$43.32	$203,601	Direct
Jan 3, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	21,667	-	$0	Direct
Jan 3, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	44,533	-	$0	Direct
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Sale(S)	9,265	$76.94	$712,803	Direct
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Sale(S)	23,082	$77.68	$1,793,019	Direct
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Sale(S)	15,825	$78.69	$1,245,280	Direct
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Sale(S)	6,050	$79.78	$482,665	Direct
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Sale(S)	7,967	$80.65	$642,545	Direct
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Sale(S)	1,206	$81.44	$98,222	Direct
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Exercise(M)	4,251	$4.68	$19,895	Direct
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Exercise(M)	12,750	$7.77	$99,068	Direct
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Exercise(M)	26,000	$5.80	$150,800	Direct

1-25 of 28 transactions

About ZANTE GREG

ZANTE GREG (SEC CIK 0001264949) files insider reports with the SEC as Chief Financial Officer of Viking Therapeutics, Inc. (VKTX).

Signal8 holds 6 ownership filings by ZANTE GREG, all Form 4s, filed between Oct 28, 2024 and Jul 29, 2026. Those filings report 28 transactions, from Oct 28, 2024 to Jul 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on ZANTE GREG's filings is in SAN DIEGO, CA.

Recent filings by ZANTE GREG

Jul 29, 2026: Open-market sale of VKTX shares (Form 4, code S).
Jul 28, 2026: Grant or award of VKTX shares (Form 4, code A).
Jan 5, 2026: Open-market sales of VKTX shares (4 lines, Form 4, code S).
Jan 2, 2026: Grants or awards of VKTX shares (2 lines, Form 4, code A).
Oct 28, 2025: Open-market sale of VKTX shares (Form 4, code S).

Other insiders filing for Viking Therapeutics, Inc. (VKTX)

Kelly-Gemmell Dorothy Elizabeth, Director
Lian Brian, President & CEO
Mancini Marianna, Chief Operating Officer
Chen Hubert C, Chief Medical Officer
Aubuchon Neil William, Chief Commercial Officer
SINGLETON J MATTHEW, Director

How to read Form 4 transaction codes